Gadeta Overview
- Founded
-
2015

- Status
-
Private
- Employees
-
38

- Latest Deal Type
-
Early Stage VC
- Investors
-
4
Gadeta General Information
Description
Developer of innovative immunotherapies designed to treat cancer. The company's innovative immunotherapies are based on the discoveries regarding the role of yo T cell receptors (TCR's) in the broad recognition of hematological and solid tumor cells and their potential use for the treatment of advanced malignancies, enabling healthcare institutions and cancer patients to eradicate both hematological and solid tumors lowering the chances of cancer.
Contact Information
Website
www.gadeta.nl
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- Yalelaan 62
- 3584 CM Utrecht
- Netherlands
+31 085 000 0000
Gadeta Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Early Stage VC | 19-Jul-2018 | 00.000 | Completed | Generating Revenue | ||
2. Early Stage VC (Series A) | 29-Mar-2016 | 00.000 | 00.000 | Completed | Startup | |
1. Seed Round | Completed | Startup |
Gadeta Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of innovative immunotherapies designed to treat cancer. The company's innovative immunotherapies are based on
Biotechnology
Utrecht, Netherlands
38
As of 2022
00.000
0000000000 0
00.000
Gadeta Competitors (79)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Pyxis Oncology | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
0000000 0000000000 | Venture Capital-Backed | Philadelphia, PA | 00 | 00000 | 00000000000 | 00000 |
000000 00000000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 0000000000 0 | 00000 |
000000-000 0000000 | Venture Capital-Backed | Palo Alto, CA | 00 | 00000 | 0000000000 | 00000 |
Gadeta Patents
Gadeta Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2013240658-A1 | Combinatorial gamma 9 delta 2 t cell receptor chain exchange | Granted | 28-Mar-2012 | 00000000000 | |
AU-2013240658-B2 | Combinatorial gamma 9 delta 2 t cell receptor chain exchange | Active | 28-Mar-2012 | 00000000000 | |
EP-2831109-B1 | Combinatorial gamma 9 delta 2 t cell receptor chain exchange | Active | 28-Mar-2012 | 00000000000 | |
US-20150050670-A1 | Combinatorial gamma 9 delta 2 t cell receptor chain exchange | Granted | 28-Mar-2012 | 00000000000 | |
AU-2017204731-B2 | Combinatorial gamma 9 delta 2 t cell receptor chain exchange | Active | 28-Mar-2012 | G01N33/5011 |
Gadeta Executive Team (8)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Marcel Zwaal | Chief Executive Officer | ||
Jurgen Kuball MD | Co-Founder | ||
Mark Throsby Ph.D | Chief Scientific Officer & Chief Operating Officer |
Gadeta Board Members (7)
Name | Representing | Role | Since |
---|---|---|---|
Giovanni Mariggi Ph.D | Medicxi | Board Member | 000 0000 |
Mark De Boer Ph.D | Medicxi | Board Member | 000 0000 |
Michèle Ollier MD | Medicxi | Board Member | 000 0000 |
Gadeta Signals
Gadeta Investors (4)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Kite Pharma | Corporation | Majority | 000 0000 | 000000 0 | |
Baxalta Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Medicxi | Venture Capital | Minority | 000 0000 | 000000 0 | |
Utrecht Holdings | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 |